AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Thyrotropin-releasing hormone-degrading ectoenzyme

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9UKU6

UPID:

TRHDE_HUMAN

Alternative names:

Pyroglutamyl-peptidase II; TRH-specific aminopeptidase; Thyroliberinase

Alternative UPACC:

Q9UKU6; A5PL19; Q6UWJ4

Background:

The Thyrotropin-releasing hormone-degrading ectoenzyme, also known as Pyroglutamyl-peptidase II, TRH-specific aminopeptidase, or Thyroliberinase, plays a crucial role in the specific inactivation of TRH after its release. This protein is encoded by the gene with the accession number Q9UKU6.

Therapeutic significance:

Understanding the role of Thyrotropin-releasing hormone-degrading ectoenzyme could open doors to potential therapeutic strategies. Its precise function in regulating TRH, a critical hormone in the thyroid axis, suggests its involvement in maintaining hormonal balance and metabolic health.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.